Hydra Biosciences, Cubist form collaboration

Hydra Biosciences has announced an agreement with Cubist Pharmaceuticals Inc. for a joint collaboration to develop novel ion channel drugs.
Register for free to listen to this article
Listen with Speechify
0:00
2:00
 

CAMBRIDGE, Mass. ­– Hydra Biosciences has announced an agreementwith

Cubist Pharmaceuticals Inc. for a joint collaboration todevelop novel ion channel drugs.

 

The deal focuses on Hydra's research and development programfor ion channel compounds that target the TRPA1 receptor, which is believed tohave an important role in pain management.

 

Under the terms of the agreement, Hydra receives an upfrontpayment of $5 million from Cubist. The agreement allows for Cubist to supportHydra`s internal development on the TRPA1 program by providing $5M in researchand development funding per year for two years, with an option to renew. Thejoint development program will build on the existing R&D base of Hydra`sTRPA1 compounds, preclinical data, and pharmacology studies. As thecollaboration progresses into potential future stages, Hydra is eligible for potentialdevelopment milestones and royalties on products produced from the jointprogram. The goal of the program is to identify TRPA1 drug candidates for useas acute care therapeutics for the management of pain.

 

"As we continue to build an acute care pipeline, we areexcited to develop a partnership with Hydra that provides us access to a novelplatform for developing acute care therapeutics for the management ofpain," says Steven Gilman, Ph.D., chief scientific officer of CubistPharmaceuticals.

 

"Weare pleased to collaborate with Cubist and to advance innovative drug candidatesusing our ion channel platform," says Russell Herndon, Chief ExecutiveOfficer of Hydra Biosciences. "While our platform has potentially broadapplications in the treatment of pain, inflammation, cardiovascular and otherdiseases, this collaboration is a step forward in advancing our pipeline fornovel ion channel drugs for pain management."  

Related Topics

Published In

Loading Next Article...
Loading Next Article...
Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

Close-up illustration of clustered, irregularly shaped 3D cell structures resembling organoids, displayed in a blue-toned background.
Machine learning-powered image analysis makes it possible to automatically and reliably quantify complex 3D cell structures.
Illustration of a glowing human brain with interconnected neural networks and bright data points, set against a dark, digital background.
Take a closer look at modern techniques that reveal when, where, and how neurons communicate in real time.
Gloved hand holding a petri dish containing red liquid culture medium against a light blue background.
As global regulations shift toward animal-free testing, how can researchers develop more biologically relevant in vitro models to advance drug discovery?
Drug Discovery News June 2025 Issue
Latest IssueVolume 21 • Issue 2 • June 2025

June 2025

June 2025 Issue

Explore this issue